Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035172 | 0.95 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL26128395 | 0.94 | ITGB1 (0.60) | ITGB1ITGA4 | |
| SCHEMBL26128394 | 0.94 | ITGB1 (0.60) | ITGB1ITGA4 | |
| SCHEMBL12642639 | 0.90 | ITGB1 (0.55) | ITGB1ITGA4 | |
| SCHEMBL5208748 | 0.88 | CTSD (0.49) | ITGB1ITGA4 | |
| SCHEMBL2414308 | 0.86 | ITGB1 (0.53) | ITGB1ITGA4 | |
| SCHEMBL26126983 | 0.85 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL26126969 | 0.85 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL26126988 | 0.85 | ITGB1 (0.52) | ITGB1ITGA4 | |
| SCHEMBL13768979 | 0.84 | ITGB1 (0.52) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327514-A1 | COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR | CENTOCOR RESEARCH & DEVELOPMENT, INC. | 2024-10-03 | — | — | US | claimed |
| US-20240228618-A1 | COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND AN ANTI-CD44 THERAPEUTIC | JANSSEN BIOTECH INC (US) | 2024-07-11 | — | — | US | claimed |
| EP-4340942-A1 | COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND AN ANTI-CD44 THERAPEUTIC | Janssen Biotech, Inc. (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117396226-A | Compositions comprising a T cell redirecting therapeutic agent and an anti-CD 44 therapeutic agent | 詹森生物科技公司 | 2024-01-12 | — | — | CN | claimed |
| CN-115666727-A | Compositions comprising a T cell redirecting therapeutic agent and a VLA-4 adhesion pathway inhibitor | 詹森生物科技公司 | 2023-01-31 | — | — | CN | claimed |
| WO-2022243838-A1 | COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND AN ANTI-CD44 THERAPEUTIC | JANSSEN BIOTECH, INC. (US) | 2022-11-24 | — | — | WO | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| US-12419619-B2 | Aspiration device | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | disclosed |
| EP-1922313-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007017096-A1 | PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | ITGB1 4765/4885ITGA4 4795/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | ITGB1 3270/4885ITGA4 2741/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | ITGB1 3502/4885ITGA4 2905/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | ITGB1 685/4885ITGA4 3028/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | ITGB1 2364/4885ITGA4 3244/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | ITGB1 27/4885ITGA4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.